<DOC>
	<DOCNO>NCT00090090</DOCNO>
	<brief_summary>To determine safety efficacy elsamitrucin patient relapse refractory non-Hodgkin 's lymphoma ( NHL ) . To determine elsamitrucin efficacious particular pathologic NHL subtype ( ) .</brief_summary>
	<brief_title>Elsamitrucin ( SPI 28090 ) Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Elsamicin A</mesh_term>
	<criteria>Relapsed Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt 's , Burkitt 's like HIVassociated lymphoma least one prior cytotoxic chemotherapy regimens measurable disease adequate bone marrow , liver kidney function ECOG PS 02 prior treatment elsamitrucin prior chemo , antibody radiotherapy NHL within 28 day prior start treatment HIV positive know AIDS syndrome uncontrolled medical disease psychiatric condition/s</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>